Hyperthermia involves raising the temperature of tumor tissues selectively to damage and kill cancer cells or to make tumor cells more sensitive to the effects of radiation and certain anticancer drugs. Hyperthermia treatments damage cancer cells by heating them through energy sources such as electromagnetic radiation, ultrasound, or circuits implanted in the body. These therapies have fewer side effects than other treatments such as chemotherapy.
The global Hyperthermia Cancer Treatment Market is estimated to be valued at US$ 187.05 Bn in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends
Advanced Targeting Technologies: One of the key trends driving growth in the hyperthermia cancer treatment market is the development of advanced targeting technologies that allow more selective heating of cancer cells. Technologies such as magnetic nanoparticles, high-intensity focused ultrasound (HIFU), and radiofrequency ablation guide enhanced energy deposition at the tumor site. This minimizes damage to surrounding healthy tissues and increases treatment efficacy. Nanoparticles like iron oxide nanoparticles can be injected systemically or locally and heated using an alternating magnetic field. When targeted to tumors through magnetic guiding, they induce selective tumor hyperthermia.
Segment Analysis
The hyperthermia cancer treatment market is dominated by the regional segment that represents around 35% share of the global market. Region-specific treatment techniques are more effective and witnessing higher adoption. The regional technique is effective in raising the temperature of tumors located near the skin’s surface or in subcutaneous fat without raising the body's core temperature too much. It is more effective for treating cancers like melanoma, lymphoma, soft tissue cancers etc. That’s why the regional segment continues to be the largest sub-segment in the global market.
Key Takeaways
The Global Hyperthermia Cancer Treatment Market Demand is expected to witness high growth over the forecast period. The market growth can be attributed to rising geriatric population, increasing prevalence of cancer cases, improving reimbursement policies, and growing adoption of minimally invasive procedures. The global Hyperthermia Cancer Treatment Market is estimated to be valued at US$ 187.05 Bn in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023 to 2030.
Regional analysis
North America holds the largest share in the global hyperthermia cancer treatment market due to highly developed healthcare infrastructure, availability of advanced treatment options, and growing incidence of cancer cases. Moreover, presence of key players and favorable reimbursement policies in the region boost the market growth. Asia Pacific is expected to witness fastest growth during the forecast period owing to expanding healthcare infrastructure, growing medical tourism industry, and increasing healthcare spending in the region.
Key players
Key players operating in the hyperthermia cancer treatment market are Allergan plc. (A subsidiary of AbbVie Inc.),Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Merck KGaA, GSK plc., AstraZeneca., Baxter, Novartis AG, F. Hoffmann-La Roche Limited, Shire (A subsidiary of Takeda Pharmaceutical Company Limited) and Sanofi. Allergan plc, Novo Nordisk A/S and Boehringer Ingelheim International GmbH hold major market share.
Explore more information on this topic, Please visit-
https://www.marketwebjournal.com/hyperthermia-cancer-treatment-market-growth-and-trnds-analysis-share-size-demand-forecast/
Comments
0 comment